| Description | Tenatumomab (ST2146) is a murine anti-tenascin-C monoclonal antibody used in the study of immune system diseases and lymphomas. |
| In vitro | 与其他抗肌腱蛋白单克隆抗体相比，Tenatumomab (2-5 μg/mL; 16 h) 生物素化后仍能保持 50% 的免疫反应性[2]。 |
| In vivo | Tenatumomab（4 μg/鼠；静脉注射；单次剂量）在移植HT-29结肠癌细胞和/或U-118MG胶质母细胞瘤细胞的裸鼠中表现出与低和高张力蛋白表达相关的生物分布特性[2]。 |
| Synonyms | ST 2146, ST2146, ST-2146 |
| molecular weight | N/A |
| CAS | 1412891-40-7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253. 2. De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6. |